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The classification of gliomas has undergone major 
changes through the revision of the fourth edition of the 
WHO Classification of Tumors of the Central Nervous 
System1 in 2016. Further refinements of the classifica-
tion were subsequently proposed by the Consortium 
to Inform Molecular and Practical Approaches to 
CNS Tumour Taxonomy — Not Officially WHO 
(cIMPACT- NOW)2–4. These documents enable a diag-
nosis of glioblastoma to be made not only based on 
histology but also on the basis of several molecular 
markers and propose the discontinuation of the term 
‘IDH- mutant glioblastoma’. To reflect these changes, 
the European Association of Neuro- Oncology (EANO) 
considered it necessary to update its guidelines for the 
management of adult patients with gliomas5 (Box 1). In 
the present evidence- based guidelines, we cover the 
prevention, early diagnosis and screening, integrated 
histo molecular diagnostics, therapy and follow- up mon-
itoring of adult patients with diffuse gliomas. Aspects 
such as differential diagnosis, adverse effects of treat-
ment, and supportive and palliative care are beyond the 
scope of this guideline document.
Methods
These evidence- based guidelines were formulated by 
a task force nominated by the EANO Executive Board 
following a proposal by the Chair of the EANO guide-
lines committee. This task force includes representa-
tives of all the disciplines involved in the diagnosis and 
care of adults with glioma and reflects the multinational 
character of EANO. References were retrieved from the 
PubMed database using the search terms ‘glioma’, ‘ana-
plastic’, ‘astrocytoma’, ‘oligodendroglioma’, ‘glioblastoma’, 
‘trial’, ‘clinical’, ‘surgery’, ‘radiotherapy’ and ‘chemother-
apy’ between January 2011 and July 2020. Publications 
were also identified through searches of the authors’ own 
libraries. Only publications in English were reviewed. 
Data available only in abstract form were included in 
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Abstract | In response to major changes in diagnostic algorithms and the publication of mature 
results from various large clinical trials, the European Association of Neuro- Oncology (EANO) 
recognized the need to provide updated guidelines for the diagnosis and management of adult 
patients with diffuse gliomas. Through these evidence- based guidelines, a task force of EANO 
provides recommendations for the diagnosis, treatment and follow- up of adult patients with 
diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification 
of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium 
to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy — Not Officially WHO 
(cIMPACT- NOW). With regard to therapy, we formulated recommendations based on the results 
from the latest practice- changing clinical trials and also provide guidance for neuropathological 
and neuroradiological assessment. In these guidelines, we define the role of the major treatment 
modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances 
and cognizant that unnecessary interventions and expenses should be avoided. This document  
is intended to be a source of reference for professionals involved in the management of adult 
patients with diffuse gliomas, for patients and caregivers, and for health- care providers.
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exceptional circumstances. The definitive reference list 
was generated based on relevance to the broad scope of 
these guidelines. The consensus recommendations were 
achieved through repeated circulation of manuscript 
drafts and telephone conferences involving members of 
the task force to discuss the most controversial areas. 
The key recommendations for the diagnosis and man-
agement of diffuse gliomas of adulthood, with their class 
of evidence (C) and level of recommendation (L)6 are 
reported at the end of each corresponding paragraph.
Epidemiology and prevention
The annual incidence of gliomas is approximately of 
six cases per 100,000 individuals worldwide. Men are 
1.6- fold more likely to be diagnosed with gliomas than 
women7. While the vast majority of cases are sporadic, 
certain familial tumour syndromes are associated with 
gliomagenesis, including neurofibromatosis type I, 
tuberous sclerosis, Turcot syndrome, Li–Fraumeni 
syndrome and Lynch syndrome. Screening with neuro-
imaging is limited to patients with such syndromes at 
the initial diagnostic work- up8. Repeat neuroimaging 
is not indicated unless new neurological symptoms and 
signs, such a seizures, aphasia, hemiparesis or sensory 
deficits, develop that suggest an intracranial lesion. The 
counselling and screening of asymptomatic relatives 
of patients with glioma who are found to be carriers of 
germline mutations associated with gliomagenesis 
should be conducted with caution and in cooperation 
with clinical geneticists. No known measures to prevent 
the development of gliomas exist.
History and clinical examination
The evolution of neurological symptoms and signs 
enables the estimation of the growth dynamics of glio-
mas: tumours that cause symptoms only weeks before 
diagnosis are usually fast growing whereas those that 
cause symptoms for years before being diagnosed are 
usually slow growing. In most individuals, the symp-
toms and signs reported the year before diagnosis are 
non- specific (for example, fatigue or headache)9–11. 
A discussion of the patient’s history might reveal famil-
ial risk or rare exogenous risk factors (such as exposure 
to radiation) associated with the development of brain 
tumours. Information from relatives might be required 
to obtain a reliable history. Firm recommendations on 
when and how to involve family members and caregiv-
ers and how to assess the medical decision- making 
capacity in patients with brain tumours remain to be 
developed12.
Characteristic modes of clinical presentation include 
new- onset epilepsy, focal deficits (such as pareses or 
sensory disturbances), neurocognitive impairment, and 
symptoms and signs of increased intracranial pressure. 
The physical examination of patients with brain tumours 
focuses on the detection of systemic cancer to differen-
tiate primary brain tumours from brain metastases and 
contraindications for neurosurgical procedures. The 
Neurological Assessment in Neuro- Oncology (NANO) 
scale can be used to document some of the results of the 
neurological examination13. Neurocognitive assessment 
using a standardized test battery14, beyond documenting 
performance status and performing a Mini Mental State 
Examination (MMSE)15 or a Montreal Cognitive Assess-
ment (MoCA)16, has become increasingly common. 
Despite its limitations, the MMSE is widely used as a 
screening instrument to detect neurocognitive impairment 
and remains freely available for individual use.
Recommendations. 
•	Karnofsky performance score (KPS), neurologi-
cal function, age, and individual risks and benefits 
should be considered for clinical decision- making. 
C: IV; L: A.
•	 Screening and prevention have no major role for 
patients with gliomas. C: IV; L: C.
•	 Patients with relevant germline variants or suspected 
hereditary cancer syndromes should receive genetic 
counselling and might subsequently be referred for 
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Preoperative diagnostics
Brain MRI, including T2- weighted, T2- weighted 
fluid- attenuated inversion recovery (FLAIR) sequences 
and 3D T1- weighted sequences before and after applica-
tion of a gadolinium- based contrast agent, is the diagnos-
tic gold standard to detect a brain tumour17. Perfusion 
MRI and amino acid PET can help to define metabolic 
hotspots for specific tumour tissue sampling, a technique 
that can be particularly useful if biopsy rather than open 
resection is considered18. Electroencephalography can be 
helpful in the monitoring of tumour- associated epilepsy 
and in determining the cause of altered consciousness. 
A large number of studies has shown that cell- free 
tumour DNA can be detected in the plasma and cerebro-
spinal fluid of patients with glioma; however, the benefits 
of using liquid biopsies for the screening, early detec-
tion or preoperative work- up of patients with gliomas 
remain to be proven19.
Recommendations. 
•	The first choice of diagnostic imaging modality 
is MRI without and with the administration of a 
gadolinium- based contrast agent. C: IV; L: B.
•	 Pseudoprogression should be considered in patients 
with an increase of abnormalities on neuroimaging in 
the first months after local therapeutic interventions, 
including radiotherapy, and after experimental local 
treatments. C: IV; L: B.
Preoperative management
Patient management before surgery should follow 
written local standard operating procedures and 
involve multidisciplinary discussions, ideally by a 
dedicated multidisciplinary tumour board including 
neuroradiologists and neuropathologists as well as 
neurosurgeons, radiation oncologists and dedicated 
neuro- oncologists from neurology or medical oncol-
ogy services and from paediatric oncology as needed. 
Prior to surgery, corticosteroids can be administered to 
decrease symptomatic tumour- associated oedema unless 
primary cerebral lymphoma or inflammatory lesions are 
suspected. Alternative pharmacological measures, such 
as osmotic agents, are rarely necessary. Patients who 
have suffered epileptic seizures should receive anticon-
vulsant drugs preoperatively. Primary prophylaxis does 
not reduce the risk of a first seizure in patients with 
glioma without a history of seizures20.
Tissue acquisition
Treatment decisions in patients with glioma are made 
based on tissue diagnosis, including the assessment of 
molecular markers relevant for diagnosis; therefore, 
upfront surgery is commonly performed with both diag-
nostic and therapeutic intent. The surgical management 
of patients with glioma should take place in high- volume 
specialist centres where large numbers of patients are 
referred to specialist neurosurgeons21. A decision for pal-
liative care management without histological diagnosis 
should be avoided unless the risk of adverse outcomes 
from biopsy sampling is considered too high or if the 
prognosis is likely to be very unfavourable, for example, 
in patients with a high burden of comorbidities, large 
lesions with a typical radiological appearance of glioblas-
toma and rapid neurological deterioration. Definitive 
histological diagnoses aid in the counselling of patients 
and caregivers, even when no further tumour- specific 
therapy is recommended.
When microsurgical resection is not safely feasi-
ble (for example, owing to the tumour location or the 
impaired clinical condition of the patient), a stereotactic 
biopsy should be performed. Frame- based or frame- less 
stereotactic biopsy sampling is associated with a low risk 
of morbidity and a high level of diagnostic accuracy22,23. 
Serial samples of the tumour mass should be acquired 
along the trajectory of the biopsy needle in order to 
avoid sampling bias. Experienced teams can derive ade-
quate tissue specimens for molecular profiling using 
these techniques22. IDH mutations and 1p/19q code-
letion as disease- defining markers as well as MGMT 
promoter methylation24 are homogeneously present 
within tumours and, thus, the risk of sampling error for 
these markers is low. However, for additional markers 
of interest for which homogeneity has not been shown, 
sampling has to include different areas of the tumour; 
this principle applies for both stereotactic and open 
procedures. Intraoperative use of the fluorescent dye 
5- aminolevulinic acid can be helpful to ensure adequate 
sampling during stereotactic biopsies25. Some centres 
prefer open biopsy approaches to ensure that sufficient 
tissue is obtained for any molecular studies that might be 
required to guide clinical decision- making.
Recommendations. 
•	Clinical decision- making without obtaining a tis-
sue diagnosis should be considered only in very 
exceptional situations. C: IV; L: not applicable.
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Integrated histomolecular classification
Intraoperative assessment of cytological specimens or 
frozen sections ensures that sufficient tumour tissue is 
obtained to establish a diagnosis. Tumour tissue is for-
malin fixed and embedded in paraffin for histological 
and immunohistochemical staining as well as for molec-
ular genetic and cytogenetic studies. If possible, some 
tumour tissue should be cryopreserved for molecular 
assessments that require high- quality DNA and RNA 
samples. The diagnostic process should follow the WHO 
classification of 2016 (ref.1) and the subsequent recom-
mendations from cIMPACT- NOW2–4. Accordingly, gli-
oma classification integrates histological tumour typing 
and grading as well as analyses of molecular markers 
(fig. 1). The term ‘not otherwise specified’ was intro-
duced to refer to gliomas that were not tested for mark-
ers relevant to the diagnosis of specific subtypes or for 
which testing was inconclusive1.
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Fig. 1 | Diagnostic algorithm for the integrated classification of the major diffuse gliomas in adults. Tissue specimens 
obtained through biopsy sampling in patients with diffuse gliomas are routinely assessed by immunohistochemistry for 
the presence of R132H- mutant IDH1 and loss of nuclear ATRX. In patients aged >55 years with a histologically typical 
glioblastoma, without a pre- existing lower grade glioma, with a non- midline tumour location and with retained nuclear 
ATRX expression, immunohistochemical negativity for IDH1 R132H suffices for the classification as IDH- wild- type 
glioblastoma1. In all other instances of diffuse gliomas, a lack of IDH1 R132H immunopositivity should be followed by  
IDH1 and IDH2 DNA sequencing to detect or exclude the presence of non- canonical mutations. IDH- wild- type diffuse 
astrocytic gliomas without microvascular proliferation or necrosis should be tested for EGFR amplification, TERT promoter 
mutation and a +7/–10 cytogenetic signature as molecular characteristics of IDH- wild- type glioblastomas2. In addition, 
the presence of histone H3.3 G34R/V mutations should be assessed by immunohistochemistry or DNA sequencing to 
identify H3.3 G34- mutant diffuse hemispheric gliomas, in particular in young patients with IDH- wild- type gliomas (such  
as those <50 years of age with nuclear ATRX loss in tumour cells). Diffuse gliomas of the thalamus, brainstem or spinal  
cord should be evaluated for histone H3 K27M mutations and loss of nuclear K27- trimethylated histone H3 (H3K27me3) 
to identify H3 K27M- mutant diffuse midline gliomas. The presence and absence of the diagnostically most relevant 
molecular alterations for each tumour type are highlighted with red and green boxes. MVP, microvascular proliferation.
www.nature.com/nrclinonc
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On the basis of the 2016 WHO classification and 
cIMPACT- NOW recommendations, the following 
molecular biomarkers are central to categorizing diffuse 
gliomas in adults: IDH mutation, 1p/19q co- deletion, his-
tone H3 K27M mutation, histone H3.3 G34R/V muta tion, 
TERT promoter mutation, EGFR gene amplifi cation, 
chromosome 7 gain combined with chromosome 10 
loss (the +7/–10 signature), and homozygous deletions 
on 9p21 involving the CDKN2A and CDKN2B gene loci 
(CDKN2A/B homozygous deletion) (TaBle 1). Missense 
mutations in codon 132 of IDH1 or codon 172 of IDH2 
are the defining molecular feature of IDH- mutant astro-
cytomas and are associated with the glioma CpG island 
methylator phenotype (G- CIMP). Diffuse gliomas cor-
responding histologically to WHO grade 2 or 3 that 
are immunohistochemically negative for IDH1 R132H 
should be sequenced for less common IDH1 and for 
IDH2 mutations. IDH- mutant astrocytomas usually also 
have loss of nuclear expression of ATRX and mutations in 
TP53 but, by definition, lack 1p/19q codeletion1. Indeed, 
the detection of nuclear ATRX loss in an IDH- mutant 
glioma is sufficient for the diagnosis of an astrocytic 
lineage tumour without the need for 1p/19q codeletion 
analysis. By contrast, retained nuclear ATRX positivity 
in an IDH- mutant glioma should prompt analysis for 
1p/19q codeletion in order to distinguish IDH- mutant 
astrocytoma from IDH- mutant and 1p/19q- codeleted 
oligodendroglioma. ATRX immuno histochemistry is 
not necessary if IDH mutation and 1p/19q codeletion 
status are captured within one more extensive mole c-
ular marker panel assay. IDH- mutant astrocytomas are 
now stratified into three WHO grades: astrocytoma, 
IDH- mutant, WHO grade 2; astrocytoma, IDH- mutant, 
WHO grade 3 (instead of anaplastic astrocytoma, 
IDH- mutant, WHO grade 3); and astrocytoma, IDH- 
mutant, WHO grade 4 (replacing the former term ‘glio-
blastoma, IDH- mutant, WHO grade 4’)3. The term 
‘glio blastoma’ is no longer used to refer to IDH- mutant 
astrocytic gliomas because these tumours are biologically 
distinct from the much more common IDH- wild- type 
glioblastomas, although their histological appearance is 
similar3. In addition to the established histological fea-
tures, such as the presence of necrosis and/or microvas-
cular proliferation, homozygous CDKN2A/B deletion is 
indicative of a poor prognosis26 and is a marker of WHO 
grade 4 IDH- mutant astrocytomas3. As the diagnostic 
Table 1 | Molecular markers for the diagnosis and management of gliomas
Molecular marker Biological function of affected genes Diagnostic roles
IDH1 R132 or IDH2 
R172 mutation
Gain- of- function mutation Distinguishes diffuse gliomas with IDH 
mutation from IDH- wild- type glioblastomas 
and other IDH- wild- type gliomas
1p/19q codeletion Inactivation of putative tumour suppressor genes 
on 1p (such as FUBP1) and 19q (such as CIC)
Distinguishes oligodendroglioma, 
IDH- mutant and 1p/19q- codeleted from 
astrocytoma, IDH- mutant
Loss of nuclear 
ATRX
Cell proliferation and promotion of cellular 
longevity by alternative lengthening of telomeres
Loss of nuclear ATRX in an IDH- mutant glioma 
is diagnostic for astrocytic lineage tumours
Histone H3 K27M 
mutation
Histone H3.3 (H3F3A) or histone H3.1 
(HIST1H3B/C) missense mutation affecting 
epigenetic regulation of gene expression
Defining molecular feature of diffuse midline 
glioma, H3 K27M- mutant
Histone H3.3 
G34R/V mutation
Histone mutation affecting epigenetic regulation 
of gene expression
Defining molecular feature of diffuse 
hemispheric glioma, H3.3 G34- mutant
MGMT promoter 
methylation
DNA repair None, but is a predictive biomarker of benefit 
from alkylating chemotherapy in patients 




Encode cyclin- dependent kinase inhibitors 
2A and 2B and tumour suppressor ARF, which 
function as regulators of Rb1 and p53- dependent 
signalling
A marker of poor outcome and WHO grade 4 
disease in IDH- mutant astrocytomas
EGFR amplification Cell proliferation, invasion and resistance to 
induction of apoptosis
EGFR amplification occurs in ~40–50% of 
glioblastoma, IDH wild type
Molecular marker of glioblastoma, 
IDH wild type, WHO grade 4 (ref.3)
TERT promotor 
mutation
Cell proliferation; promotes cellular longevity  
by increasing TERT expression
TERT promoter mutation occurs in  
~70% of glioblastoma, IDH wild type and 
>95% of oligodendroglioma, IDH- mutant  
and 1p/19q- codeleted
Molecular marker of glioblastoma,  
IDH wild type, WHO grade 4 (ref.3)
+7/–10 cytogenetic 
signature
Gain of chromosome 7 (harbouring genes 
encoding, among others, PDGFA and EGFR) 
combined with loss of chromosome 10 
(harbouring genes including PTEN and MGMT)
Molecular marker of glioblastoma,  
IDH wild type, WHO grade 4 (ref.3)
BRAFV600E mutation Oncogenic driver mutation leading to  
MAPK pathway activation
Rare in adult diffuse gliomas but amenable  
to pharmacological intervention
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term ‘astrocytoma, IDH- mutant’ can be associated with 
different tumour grades and the roman numerals II and 
III are easily confused, cIMPACT- NOW recommended 
the use of Arabic numerals for the WHO- based grad-
ing of these tumours3. In line with the sixth update 
of the cIMPACT- NOW recommendations4, in these 
evidence- based guidelines we use Arabic numerals for 
WHO grades.
Special attention should be given to diffuse astro-
cytomas in the brainstem or cerebellum with his-
to logies corresponding to WHO grades 2, 3 and 4. 
Among infratentorial astrocytomas, the frequency of 
non- canonical IDH mutations is ~80%, in contrast with 
<10% in those of the supratentorial compartment27,28. 
Infratentorial diffuse gliomas therefore tend to be clas-
sified incorrectly if examined by IDH1 R132H immuno-
histochemistry only; accordingly, DNA sequencing for 
rare mutations in IDH1 and IDH2 is required. In addi-
tion, infratentorial IDH- mutant astrocytomas have a loss 
of nuclear ATRX expression as well as MGMT promoter 
methylation in only ~50% of patients27,28.
Oligodendroglial tumours are defined as IDH- mutant 
gliomas that also harbour 1p/19q codeletion1 and are 
stratified into WHO grade 2 or 3 tumours based on the 
absence or presence of histological features of anapla-
sia. The role of molecular alterations in the grading of 
these tumours has not been defined. However, similar 
to IDH- mutant diffuse astrocytomas, the homozy-
gous deletion of CDKN2A at 9p21 has been associated 
with shorter survival durations29. Oligoastrocytomas 
lack characteristic genetic profiles and are no longer 
considered as a distinct glioma subtype.
Astrocytic gliomas with a wild- type IDH and histone 
H3 status and with necrosis and/or microvascular pro-
liferation are classified as IDH- wild- type, WHO grade 4 
glioblastomas1. In the absence of necrosis or microvascu-
lar proliferation, such tumours should be evaluated for 
glioblastoma- associated genetic alterations, in particular 
EGFR gene amplifications, TERT promoter mutations 
and/or the +7/–10 signature2. If one or more of these 
alterations is detected, these tumours are classified as 
IDH- wild- type glioblastomas given their association 
with a poor prognosis, even in the absence of necro-
sis and microvascular proliferation1,30. IDH- wild- type 
diffuse astrocytomas without any of these alterations, 
which cannot be assigned to other entities (for example, 
on the basis of DNA methylation profiling) are more 
often seen in paediatric, adolescent or young adult 
patients and constitute rare glioma variants that require 
further molecular assessment31.
H3 K27M- mutant, WHO grade 4 diffuse midline 
gliomas are defined as a diffuse glioma located in mid-
line structures, such as the thalamus, pons, brainstem 
and spinal cord, and carrying a lysine- to- methionine 
mutation at amino acid 27 of histone H3.3 (encoded by 
H3F3A) or histone H3.1 (encoded by HIST1H3B and 
HIST1H3C)1. H3 K27M- mutant diffuse midline glio-
mas are typically positive for nuclear immunostaining of 
H3 K27M with the corresponding loss of nuclear stain ing 
for K27- trimethylated histone H3 (H3K27me3), which 
together serve as immunohistochemical markers of this 
tumour type. H3.3 G34- mutant, WHO grade 4 diffuse 
hemispheric glioma has been proposed as a new sub-
type of malignant glioma, characterized by missense 
mutations affecting codon 34 of H3F3A4,31.
MGMT promoter methylation has limited diagnostic 
value but can guide treatment decisions on the use of 
chemotherapy with alkylating agents for patients with 
glioblastoma or other IDH- wild- type gliomas32. As out-
lined below, MGMT promoter methylation enables the 
prediction of benefit from alkylating agents in patients 
with these tumours. MGMT promoter methylation sta-
tus should be tested using methylation- specific PCR, 
pyrosequencing or methylation arrays (such as the 
MGMT- STP27 model)33. However, challenges remain, 
including: (1) establishing reliable MGMT promoter 
methylation status assays that can be used with high 
interlaboratory agreement, and (2) estimating the effect 
of limited MGMT promoter methylation, an intermedi-
ate state between the non- methylated and methylated 
phenotypes, on outcomes33. Immunocytochemistry 
is not an adequate method to determine the MGMT 
promoter methylation status34.
Next- generation sequencing- based gene pan-
els could enable the assessment of all or most genetic 
and chromosomal aberrations relevant for diagnosis 
using a single assay35,36. In addition, array- based DNA 
methylation profiling has emerged as a powerful novel 
diagnostic method that is independent of histology and 
useful in the routine diagnostic work- up37. Moreover, 
RNA sequencing- based approaches present a prom-
ising approach for the detection of oncogenic gene 
fusions with diagnostic and/or predictive value that 
can be found in rare subsets of diffuse gliomas, mainly 
IDH- wild- type glioblastomas38,39. Overall, molecular 
diagnostic algorithms for patients with glioma (fig. 1) 
should be standardized and should not result in delays 
in the administration of radiotherapy or tumour- specific 
pharmacotherapy.
Recommendations. 
•	Glioma classification should follow the most recent 
WHO Classification of Tumors of the Central 
Nervous System1, complemented by cIMPACT- NOW 
updates2–4. C: IV; L: B.
•	 Immunohistochemistry for mutant IDH1 R132H 
protein and nuclear expression of ATRX should be 
performed routinely in the diagnostic assessment of 
diffuse gliomas. C: IV; L: B.
•	 If immunohistochemistry for IDH1 R132H is nega-
tive, sequencing of IDH1 codon 132 and IDH2 codon 
172 should be conducted in all WHO grade 2 and 
3 diffuse astrocytic and oligodendroglial gliomas as 
well as in all glioblastomas of patients aged <55 years 
to enable integrated diagnoses according to the 
WHO classification and to guide treatment decisions. 
C: IV; L: B.
•	 1p/19q codeletion status should be determined 
in all IDH- mutant gliomas with retained nuclear 
expression of ATRX. C: II; L: B.
•	MGMT promoter methylation status should be 
determined in glioblastoma, notably in elderly or 
frail patients, to aid in decision- making for the use 
of temozolomide. C: I; L: B.
www.nature.com/nrclinonc
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•	CDKN2A/B homozygous deletions should be 
explored in IDH- mutant astrocytomas. C: IV; L: B.
•	Combined chromosome 7 gain and chromosome 
10 loss (+7/–10 signature), EGFR amplification 
and TERT promoter mutation should be tested in 
IDH- wild- type diffuse gliomas lacking microvas-
cular proliferation and necrosis as histological fea-
tures of WHO grade 4 to allow for a diagnosis of 
IDH- wild- type glioblastoma. C: IV; L: B.
•	Assessment of H3 K27M status should be done in 
diffuse gliomas involving the midline. C: IV; L: B.
•	 BRAFV600 mutations might be assessed in 
IDH-wild-type diffuse gliomas. C: IV; L: C.
Therapy — general recommendations
Prognostic factors. Younger age and better performance 
status at diagnosis are major therapy- independent prog-
nostic factors associated with favourable outcomes in 
adults with glioma7. Furthermore, molecular genetic 
factors, notably 1p/19q codeletion and IDH mutation 
status, had a strong prognostic value in the classifica-
tion of gliomas in the past but, since 2016, have become 
disease- defining features and are therefore no longer 
prognostic within a given disease subtype. As a result, 
MGMT promoter methylation status has become the 
single most important prognostic factor in an era in 
which the vast majority of adults with glioma are treated 
with alkylating agent- based chemotherapy.
Surgical therapy. The therapeutic goal of surgery is to 
remove as much tumour tissue as safely feasible using 
microsurgical techniques, without compromising neuro-
logical function. Several tools, including surgical naviga-
tion systems housing functional MRI or diffusion tensor 
imaging datasets and intraoperative MRI, ultrasono-
graphy, functional monitoring and fluorescence- based 
visualization of tumour tissue with 5- aminolevulinic 
acid, help in reducing postoperative residual tumour 
volumes while keeping the risk of new neurological 
deficits low40. The use of evoked potentials, electro-
myography or brain mapping in awake patients under 
local anaesthesia to monitor and preserve language 
and cognition facilitates resections in eloquent areas41. 
Preventing new permanent neurological deficits that 
might jeopardize independence, reduce quality of life 
(QOL) and increase the risk of additional complications 
that might, in turn, delay or preclude further therapy 
is more important than the extent of resection because 
diffuse gliomas are not cured by surgery. Neurological 
deficits that occur because of surgery can sometimes be 
predicted preoperatively. In exceptional situations, anti-
cipated minor deficits (such as quadrantanopia) might 
be deemed acceptable but only after a thorough process 
of shared decision- making42. Patients and their caregiv-
ers should also be informed that neurosurgery is always 
associated with some unpredictable risks. Postoperative 
deficits owing to emerging surgical complications are a 
negative prognostic factor that can interfere with further 
treatment and health- related QOL is of high priority to 
patients and their caregivers43. The extent of resec-
tion should be assessed within 24–48 hours of surgery 
through MRI (or CT if MRI is not possible), without and 
with contrast; MRI should include diffusion- weighted 
sequences to enable the detection of perioperative 
ischaemia44.
The role of the extent of resection and residual 
tumour volume as prognostic factors remains contro-
versial within the neuro- oncology community because 
randomized controlled trials (RCTs) addressing this 
question are very difficult to perform, and almost 
no such trials exist. A lesser extent of resection and 
larger post- surgical residual tumour volumes are neg-
ative prognostic factors across gliomas of all grades 
and subtypes45,46. These observations have resulted 
in the multitude of technical developments to maxi-
mize the extent of resection summarized above. 
Nevertheless, whether and why the extent of resection 
truly matters remain controversial questions. First, 
rather than the percentage of extent of resection, cli-
nicians might need to consider the absolute volume of 
remaining tumour tissue, including both enhancing 
and non- enhancing tumour tissue45–47. Second, early 
(<3 weeks) as opposed to later (3–5 weeks) initiation 
of postsurgical radiotherapy does not correlate with 
improved overall survival (OS)48. This finding is unex-
pected because one might predict that a longer time 
interval between surgery and start of radiotherapy 
would favour regrowth of the tumour and thus confer 
a survival disadvantage47. Third, evidence indicates 
that resectable tumours have a different biology that 
is overall less malignant than that of non- resectable 
tumours, which challenges the causal relationship 
between extent of surgery and survival. For exam-
ple, in a prospective evaluation of the effect of sur-
gical resection on survival after controlling for IDH 
status, the rate of gross total resection was higher in 
patients with IDH- mutant tumours than in those with 
IDH- wild- type tumours49. Indeed, retrospective data 
indicate that biopsy is more often the type of first sur-
gery in patients with IDH- wild- type tumours than in 
patients with IDH- mutant tumours47. Attributing the 
longer survival durations associated with IDH- mutant 
versus IDH- wild- type tumours to the rate of gross 
total resection would therefore probably not be the 
correct conclusion. With these considerations, we do 
not intend to discourage efforts to achieve gross total 
resection but rather to acknowledge the limitations of 
data from retrospective uncontrolled studies.
Recommendations. 
•	The extent of resection is a prognostic factor and 
thus, efforts at obtaining complete resections are 
justified across all glioma entities. C: IV; L: B.
•	 In the current surgical approach to gliomas, the 
prevention of new permanent neurological deficits 
has higher priority than the extent of resection. 
C: IV; L: C.
Radiotherapy. The goal of radiotherapy is to improve 
local control without inducing neurotoxicity. Indeed, 
radiotherapy delayed neurological deterioration and 
increased survival in several early clinical trials conducted 
in the past century50,51. The timing, dosing and schedul-
ing of radiotherapy are determined by the disease subtype 
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and prognostic factors, including age, KPS and resid-
ual tumour volume. Radiotherapy should start within 
3–5 weeks after surgery48 and is commonly administered 
at 50–60 Gy in 1.8–2 Gy daily fractions. No evidence sug-
gests additional benefit from high- dose versus low- dose 
radiation in patients with WHO grade 2 gliomas52 and, 
for those with higher WHO grade tumours, no data 
from randomized studies support the use of doses 
>60 Gy (ref.53). Hypofractionated radiotherapy with 
a higher dose per fraction and a lower total dose (for 
example, 15 × 2.67 Gy) is appropriate in older patients 
(>65–70 years of age) and in those with a poor prognosis 
(typically defined by a KPS of <70)54.
The area of the surgical bed plus the residual 
tumour area identified on T1- weighted, T2- weighted 
and FLAIR MRI sequences is defined as the gross 
tumour volume. To account for microscopic invasion, 
a margin of 1.0–2.0 cm is added to create the clinical 
target volume, which is generally modified to include 
abnormalities visualized on the basis of T2- weighted 
or FLAIR signals (for example, oedema) and con-
strained to anatomical barriers such as ventricles, 
tentorium and falx. Finally, another margin, usually 
of 0.3–0.5 cm, is added to enable for uncertainties in 
patient set- up and treatment delivery, generating the 
planning target volume55. The use of amino acid PET 
using tracers such as [11C- methyl]-l- methionine or 
O-(2-[18F]- fluoroethyl)-l-tyrosine to improve target 
delineation for radiotherapy has been evaluated in clin-
ical trials but is not currently part of standard practice18. 
Structures at higher risk of toxicity from radiother-
apy, including the optic nerves, optic chiasm, retinae, 
lenses, brainstem, pituitary, cochleae and hippocampi, 
should be delineated. Modern, highly conformal radi-
ation techniques, including intensity- modulated radio-
therapy for newly diagnosed tumours and stereotactic 
radiotherapy and radiosurgery for recurrent tumours, 
could provide superior target coverage and sparing of 
non- malignant brain tissue. Proton or heavy ion radio-
therapy might be options to consider for patients with 
tumours close to brain regions at risk or in those with 
a favourable prognosis in order to avoid delayed toxici-
ties, but RCTs are required to determine the tolerability, 
safety and efficacy of these approaches compared with 
standard radiotherapy56,57. Accurate patient positioning 
is required for all highly conformal approaches and is 
achieved with reproducible immobilization and digital 
imaging during treatment. Interstitial brachytherapy 
approaches have been investigated over many years as an 
alternative to external beam treatment but have not yet 
been shown to have an application in routine practice58. 
An MRI scan scheduled 3–4 weeks after completion of 
radiotherapy provides a new baseline to monitor the 
further course of disease.
Pharmacotherapy. Haematology, hepatic and renal lab-
oratory values within the normal physiological ranges 
and exclusion of major lung or heart disease or infection 
are required prior to and during most pharmacological 
treatments for patients with glioma. Most patients with 
glioma receive chemotherapy with alkylating agents 
at some point in their disease course. Temozolomide, 
an oral DNA alkylating agent that penetrates the blood–
brain barrier, is the most commonly used drug in gli-
oma treatment. This agent has a favourable safety profile, 
with myelosuppression, notably thrombocytopenia, as 
its main dose- limiting toxicity59. Hepatic function also 
needs to be monitored regularly in patients receiving 
temozolomide. In contrast to temozolomide, alkylating 
agents from the nitrosourea class, such as lomustine, 
carmustine, nimustine or fotemustine, cause delayed 
(4–6 weeks) rather than early (2–3 weeks) and more often 
cumulative leukopenia and thrombocytopenia. Notably, 
the latter can necessitate treatment interruptions, dose 
reductions or even discontinuation and considera-
tion of alternative treatments. Pulmonary fibrosis has 
been observed mainly with carmustine and is rare with 
lomustine60. Lomustine is often combined with procar-
bazine and vincristine in a regimen referred to as PCV. 
Carmustine wafers implanted into the post- surgical 
cavity provided a modest OS benefit in patients with 
newly diagnosed WHO grade 3 or 4 gliomas or recur-
rent glioblastoma61,62; however, in the pivotal trial of 
this approach, patient outcomes were not statistically 
significantly different after patients with WHO grade 3 
tumours (the majority of which are now known to be 
IDH- mutant) were excluded from the survival analy-
sis. The benefit from alkylating agent chemotherapy 
demonstrated in various RCTs (described later) has to 
be weighed against the potential long- term toxicities 
and the risk of inducing a hypermutator phenotype that 
is associated with a more malignant phenotype, in par-
ticular in patients with IDH- mutant gliomas, who have 
a longer life expectancy63,64.
Bevacizumab, an anti- VEGF antibody, is approved 
for the treatment of recurrent glioblastoma in the USA, 
Canada, Switzerland and several other countries out-
side the European Union, but no OS benefit has been 
demonstrated from its use65–67. Patients with glioma 
receiving systemic therapy should carry a documen-
tation of treatment, including laboratory results and 
information on complications and contraindications, 
to facilitate follow- up and to provide information to 
physicians in an emergency setting. Clinical centres 
managing patients with glioma should generate standard 
operating procedures and instructions for standard-
ized application of chemotherapy as well as for the 
manage ment of adverse events and complications from 
treatment.
Monitoring and follow- up assessments. Watch- and- wait 
strategies without histological verification carry the 
risk of underestimating the grade of malignancy when 
determined using only neuroimaging and thus require 
initial intervals of only 2–3 months between scans. 
In addition to clinical examination, MRI is the stan-
dard diagnostic measure for the evaluation of dis-
ease status or treatment response, using Response 
Assessment in Neuro- Oncology (RANO) criteria68–70 
and identical MRI protocols according to published 
recommendations71. After the completion of therapy, 
an initial interval between scans of 2–6 months is com-
mon practice for most patients depending on the disease 
histology but longer intervals might be appropriate in 
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cases of durable disease control and more benign tumours. 
Careful consideration of not only the most recent 
MRI scan but also of the complete disease trajectory 
is required, specifically in patients with slow- growing 
untreated lesions72. Conversely, in the event of suspected 
disease progression, short- term control MRI within 
4–8 weeks might be reasonable to confirm progression. 
Pseudoprogression (typically after chemoradiotherapy 
or immunotherapy) and pseudoresponse (for example, 
after anti- angiogenic therapy) are most likely to occur 
during the first 3 months of treatment but can also 
occur later70. Particular attention is needed when inter-
preting scans during this period; in case of doubt, res-
canning after shorter intervals (4–8 weeks) is a pragmatic 
approach. Perfusion MRI and amino acid PET might 
help to distinguish pseudoprogression from true disease 
progression73. Biopsy sampling is not always informative 
because viable tumour cells are regularly detected but 
their presence does not rule out pseudoprogression.
As for other non- curable diseases, patients with 
gliomas should be offered counselling by specialized 
psychologists or nurses and palliative care specialists. 
The need for occupational, speech and physical therapy 
as well as for counselling for social support should be 
assessed74.
Therapy — specific recommendations
IDH- mutant and 1p/19q- codeleted oligodendroglioma, 
WHO grade 2. Surgery is the primary treatment modal-
ity for patients with gliomas of this subtype. Following 
surgery, watch- and- wait strategies are justified in 
those with gross total resection and potentially also 
in younger patients (<40 years of age) with incomplete 
resection if the tumour has not yet caused neurological 
deficits beyond symptomatic epilepsy. If further treat-
ment bey ond surgery is deemed necessary, the standard 
of care is radiotherapy followed by PCV75. The use of 
chemotherapy alone remains investigational but might 
be an option to reduce the risk of late cognitive deficits 
in patients with large tumours owing to the favourable 
outcomes of this patient population relative to those with 
other subtypes76,77. The choice of treatment at recurrence 
depends on the initial treatment (TaBle 2, fig. 2).
IDH- mutant and 1p/19q- codeleted oligodendroglioma, 
WHO grade 3. In this subtype, the extent of resection 
is a prognostic factor78. The distinction of two grades 
(2 and 3) of IDH- mutant, 1p/19q- codeleted gliomas 
remains controversial and, accordingly, watch- and- wait 
strategies after complete resection can also be consid-
ered for younger patients (<40 years of age) with WHO 
grade 3 tumours, specifically for those without homozy-
gous CDKN2A/B deletion, although only after gross total 
resection and in the absence of neurol ogical deficits. 
Two large RCTs showed that the addition of PCV, either 
prior to or after radiotherapy, in the first- line of treat-
ment approximately doubled the OS79,80. Although these 
results stem from analyses of small cohorts of patients, 
both studies showed similar results, thus vali dating 
the findings and defining the current standard of care. 
Important open questions include: (1) whether neuro-
cognitive function and health- related QOL are preserved 
in long- term survivors treated with radiotherapy and 
PCV81, and (2) whether the same improvement in OS 
could be achieved with temozolomide- based chemo-
radiotherapy. Long- term results from the NOA-04 
trial showed that chemotherapy alone (either PCV or 
temozolomide) is not superior to radiotherapy alone 
in any molecular subgroup of anaplastic glioma, thus 
indicating that alkylating agent- based chemotherapy 
alone is unlikely to result in the same outcome as radio-
therapy followed by PCV82. The modified CODEL trial83 
will address whether temozolomide- based chemo-
radiotherapy is similarly effective as radiotherapy 
followed by PCV.
The choice of treatment at progression is influenced 
by the choice of and response to first- line therapy (fig. 2). 
Second surgery should always be considered. If neither 
radiotherapy nor alkylating agents are options owing to 
ineffectiveness or intolerance in the first- line setting, 
bevacizumab can be used for symptom control; however, 
the antitumour efficacy of bevacizumab is unknown and 
no evidence supports its combination with cytotoxic 
agents in this setting.
IDH-mutant astrocytoma, WHO grade 2. Most WHO 
grade 2 astrocytomas harbour IDH mutations. Gemisto-
cytic astrocytoma is a distinct variant of IDH-mutant 
astrocytoma, WHO grade 2. Maximal surgical resection, 
if safely feasible, is the best initial therapeutic approach84. 
Watch- and- wait strategies without the establish-
ment of an integrated diagnosis should only be con-
sidered in exceptional situations, even for patients 
with incidentally discovered lesions. Younger patients 
(pragmatic cut- off ~40–45 years of age) who are 
asymptomatic or with seizures only, can be managed 
through observation alone after gross total resection. 
Involved- field radiotherapy (50 Gy in 1.8 Gy fractions) 
should be considered for patients with incomplete 
resection and/or for patients aged >40 years. Early 
radio therapy (as opposed to radio therapy after disease 
progression) has been shown to prolong progression- free 
survival (PFS) but not OS85. The use of chemotherapy 
alone as frontline therapy remains investigational but 
might be an option if radiotherapy is not feasible, for 
example, in patients with large tumours. However, the 
PFS is probably shorter with temozolomide than with 
radiotherapy in patients with IDH- mutant, grade 2 
diffuse astrocytomas86. The RTOG 9802 trial reported 
a major prolongation of OS with the addition of PCV 
polychemotherapy to radiotherapy (54 Gy), from 
7.8 years to 13.3 years in patients with high- risk WHO 
grade 2 gliomas who were 18–39 years of age and had 
undergone a subtotal resection or biopsy or in those aged 
≥40 years75. This benefit was reported across histological 
subgroups and, although cohort sizes were small, benefit 
was observed in patients with either IDH- mutant astro-
cytomas or oligodendrogliomas but not in those with 
IDH- wild- type tumours87. Thus, radiotherapy followed 
by PCV constitutes the standard of care for patients with 
WHO grade 2 IDH- mutant astrocytomas deemed to 
require post- surgical treatment.
Treatment at progression depends on neurological 
status, patterns of progression and first- line therapy 
Nature reviews | CliniCal OnCOlOgy
e v i d e n c e - B a s e d  g u i d e l i n e s
Table 2 | Key treatment recommendations for adult patients with common diffuse gliomas
Tumour typea Treatment at diagnosisb Treatment at progression or 
recurrencec,d
Comments
Astrocytoma, IDH- mutant, WHO  
grade 2, including gemistocytic 
astrocytoma, IDH- mutant, WHO grade 2  
(cIMPACT- NOW, previously diffuse 
astrocytoma, IDH- mutant, WHO grade 2)
Wait- and- see or radiotherapy (50–54 Gy 
in 1.8–2 Gy fractions) followed by PCV (or 
temozolomide chemoradiotherapy)
Temozolomide (or nitrosourea) RTOG 9802 (ref.75) and per 
extrapolation from WHO 
grade 3 tumours88
Diffuse astrocytoma, IDH wild type, 
WHO grade 2a,e
Wait- and- see (?); radiotherapy (50–54 Gy 
in 1.8–2 Gy fractions); radiotherapy 
followed by PCV or temozolomide 
chemoradiotherapy (by MGMT status?)
Temozolomide; nitrosourea; 
bevacizumabf
Heterogeneous group of 
tumours awaiting further 
subclassificatione
Diffuse astrocytoma, NOSg, WHO grade 2 See astrocytoma, IDH- mutant, WHO 
grade 2
See astrocytoma, IDH- mutant, 
WHO grade 2
Per extrapolation because 
most of these tumours 
carry IDH mutations
Astrocytoma, IDH- mutant, WHO grade 3  
(cIMPACT- NOW, previously anaplastic 
astrocytoma, IDH- mutant, WHO grade 3)
Radiotherapy (54–60 Gy in 1.8–2 Gy 





Anaplastic astrocytoma, IDH wild type, 
WHO grade 3
Radiotherapy (54–60 Gy in 
1.8–2 Gy fractions); temozolomide 





from IDH- wild- type 
glioblastoma32,59
Anaplastic astrocytoma, NOS, WHO 
grade 3




Per extrapolation because 
most of these tumours 
carry IDH mutations
Oligodendroglioma, IDH- mutant and 
1p/19q- codeleted, WHO grade 2
Wait- and- see; radiotherapy (50–54 Gy  
in 1.8–2 Gy fractions) followed by PCV
Temozolomide Per extrapolation from 
WHO grade 3 tumours79,80 
and RTOG 9802 (ref.75)
Oligodendroglioma, NOS, WHO grade 2 See oligodendroglioma, IDH- mutant and 
1p/19q- codeleted, WHO grade 2
See oligodendroglioma, 
IDH- mutant and 1p/19q- 
codeleted, WHO grade 2
Per extrapolation because 
most of these tumours 
carry IDH mutations
Oligodendroglioma, IDH- mutant and 
1p/19q- codeleted, WHO grade 3 
(cIMPACT- NOW, previously anaplastic 
oligodendroglioma, IDH- mutant and 
1p/19q- codeleted, WHO grade 3)
Radiotherapy (54–60 Gy in 1.8–2 Gy 
fractions) followed by PCV (or 
wait- and- see)
Temozolomide 79,80
Anaplastic oligodendroglioma, NOS, 
WHO grade 3
See oligodendroglioma, IDH- mutant and 
1p/19q- codeleted, WHO grade 3
See oligodendroglioma, 
IDH- mutant and 
1p/19q- codeleted, WHO 
grade 3
Per extrapolation because 
most of these tumours 
carry IDH mutations
Oligoastrocytoma, NOS, WHO grade 2 Wait- and- see; radiotherapy (50–54 Gy in 
1.8–2 Gy fractions) followed by PCV
Temozolomide Per extrapolation from 
WHO grade 3 tumours79,80 
and RTOG 9802 (ref.75)
Anaplastic oligoastrocytoma, NOS, WHO 
grade 3
Radiotherapy (54–60 Gy in 1.8–2 Gy 
fractions) followed by PCV (or 
wait- and- see)
Temozolomide 79,80
Astrocytoma, IDH- mutant, WHO grade 4 
(cIMPACT- NOW, previously glioblastoma, 
IDH- mutant, WHO grade 4)
Temozolomide chemoradiotherapy 
(54–60 Gy in 1.8–2 Gy fractions) 




Per extrapolation from 
IDH- mutant anaplastic 
astrocytoma88 or from 
glioblastoma59
Glioblastoma, IDH wild type,  
WHO grade 4; giant cell glioblastoma; 
gliosarcoma; epithelioid glioblastoma
Temozolomide chemoradiotherapy 
(54–60 Gy in 1.8–2 Gy fractions); for 
patients aged >65–70 years and MGMT 
unmethylated tumours, radiotherapy 
(40 Gy in 2.67 Gy fractions); for patients 
aged >65–70 years and MGMT 




radiotherapy (for patients 
not previously treated with 
radiotherapy)
59,94,96–98
Glioblastoma, NOS, WHO grade 4 Temozolomide chemoradiotherapy 
(54–60 Gy in 1.8–2 Gy fractions); for 
patients aged >65–70 years and MGMT 
unmethylated tumours, radiotherapy 
(40 Gy in 2.67 Gy fractions); for patients 
aged >65–70 years and MGMT 




radiotherapy (for patients 
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(fig. 2). Second surgery should always be considered, 
usually followed by radiotherapy in patients who had 
not previously received irradiation, or by alkylating 
agent- based chemotherapy. Temozolomide is often pre-
ferred over PCV in this setting owing to its favourable 
safety profile and ease of administration.
IDH- mutant astrocytoma, WHO grade 3. The standard 
of care for patients with this disease subtype is maximal 
surgical resection or biopsy followed by radiotherapy at 
60 Gy in 1.8–2 Gy fractions (TaBle 1). This approach was 
established largely based on trials in which subgroups of 
patients with WHO grade 3 tumours were pooled with 
those with glioblastomas. The NOA-04 trial showed 
similar PFS and OS with PCV or temozolomide alone 
versus radiotherapy alone78,82. The EORTC 26053 trial 
(CATNON) of radiotherapy alone, with concomitant or 
maintenance temozolomide or with both concomitant 
and maintenance temozolomide showed a significant 
prolongation of OS in patients receiving radiotherapy 
followed by 12 cycles of maintenance temozolomide 
and, thus, this approach should be considered standard 
of care; however, the role of concomitant temozolo-
mide remains uncertain88. Indeed, updated data from 
CATNON indicate that concomitant temozolomide pro-
vides limited improvement to the overall favourable out-
comes associated with maintenance chemotherapy and, 
more importantly, that only patients with IDH- mutant 
tumours derive benefit from chemotherapy (either as 
maintenance or concomitantly)89.
First- line therapy informs the choice of treatment 
in the recurrent disease setting (fig. 2). Second surgery 
should be considered for all patients. For those with 
disease relapse after radiotherapy, re- irradiation after 
a minimum interval of ~12 months following the first 
course of radiotherapy is an option, although tumour 
size and patterns of recurrence limit the option of 
re- irradiation and the overall efficacy of this strategy 
remains uncertain in the absence of data from RCTs. 
Alkylating agent- based chemotherapy should be consid-
ered for patients who have not received previous chemo-
therapy and with disease progression after radiotherapy. 
Temozolomide and nitrosoureas are probably equally 
effective in this setting90,91. Adding bevacizumab to 
temozolomide prolongs neither PFS nor OS durations in 
patients with contrast- enhancing recurrent IDH- mutant 
gliomas without 1p/19q codeletion14.
Recommendations. 
•	The standard of care for IDH- mutant astrocyto-
mas, WHO grade 2 requiring further treatment 
includes resection as feasible or biopsy followed by 
involved field radiotherapy and maintenance PCV 
polychemotherapy (RTOG 9802)75. C: II; L: B.
•	The standard of care for IDH- mutant astrocyto-
mas, WHO grade 3 includes resection as feasible or 
biopsy followed by involved field radiotherapy and 
maintenance temozolomide (CATNON)88. C: II; L: B.
•	 Patients with IDH- mutant and 1p/19q- codeleted 
oligodendrogliomas, WHO grade 2 requiring fur-
ther treatment should be treated with radiotherapy 
followed by PCV polychemotherapy. C: III; L: B.
•	 Patients with IDH- mutant and 1p/19q- codeleted oli-
godendrogliomas, WHO grade 3 should be treated 
with radiotherapy followed by PCV polychemotherapy 
(EORTC 26951, RTOG 9402)79,80. C: II; L: B.
•	Temozolomide chemotherapy is standard treat-
ment at progression after surgery and radiotherapy 
for most patients with IDH- mutant gliomas, WHO 
grade 2 or 3. C: II; L: B.
IDH- wild- type glioblastoma, WHO grade 4. These 
tumours include histologic variants such as giant cell 
glioblastoma, gliosarcoma and epithelioid glioblastoma. 
Tumours formerly diagnosed as IDH- mutant glioblas-
toma are now referred to as IDH- mutant astrocytoma, 
WHO grade 4, and are managed either as IDH- wild- type 
glioblastoma or as IDH- mutant astrocytoma, WHO 
grade 3 (TaBle 2).
Surgery for glioblastoma should involve gross total 
resection whenever feasible46. A small RCT in patients 
aged >65 years at diagnosis of a WHO grade 3 or 4 gli-
oma reported longer OS durations with resection versus 
biopsy92, but the relevance of this trial remains debatable 
owing to the limited sample size and KPS imbalances 
between treatment groups.
For decades, radiotherapy (60 Gy in 1.8–2 Gy frac-
tions) has been the standard of care for glioblastoma, 
approximately doubling median OS durations50. Radio-
therapy (50 Gy in 1.8 Gy fractions) improved OS relative 
Tumour typea Treatment at diagnosisb Treatment at progression or 
recurrencec,d
Comments
Diffuse midline glioma, H3 K27M- mutant, 
WHO grade 4
Radiotherapy (54–60 Gy in 





Diffuse hemispheric glioma, H3.3 
G34- mutant, WHO grade 4
Temozolomide chemoradiotherapy Nitrosourea; temozolomide 
rechallenge; bevacizumabc
Per extrapolation59
According to the 2016 WHO classification1 and cIMPACT- NOW updates 3, 5 and 6 (refs2–4). NOS, not otherwise specified; PCV, procarbazine, lomustine and 
vincristine. aProvisional and NOS tumour categories are indicated in italics. bMaximum safe resection is recommended whenever feasible in all patients with newly 
diagnosed gliomas. cSecond surgery should always be considered but clinical benefit might be limited to patients in whom a gross total resection can be achieved. 
Indications for reirradiation remain controversial. dRe- exposure to temozolomide and nitrosoureas is associated with limited activity in tumours without MGMT 
promoter methylation. eDiffuse astrocytomas, IDH wild type are a heterogeneous tumour group that should be further molecularly characterized to separate 
malignant tumours with molecular features of IDH- wild- type glioblastoma from indolent tumours (for example, corresponding to paediatric- type diffuse gliomas). 
fDepending on local availability. gManagement recommendations for NOS categories are included, but evidence is low. Of note, most practice- defining trials 
included herein enrolled patients prior to the 2016 revision of the WHO classification. hTumour- treating fields remain controversial when applied in the 
temozolomide maintenance setting despite a phase III trial with positive results101 and are not widely available in Europe.
Table 2 (cont.) | Key treatment recommendations for adult patients with common diffuse gliomas
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to best supportive care in patients aged ≥70 years with a 
good KPS (≥70)51. Patients with unfavourable prognos-
tic factors (defined by age and/or KPS) can be treated 
with hypofractionated radiotherapy (such as 40 Gy in 15 
fractions), which has similar activity to irradiation with 
60 Gy in 30 fractions54. Further hypo fractionation to 
5 × 5 Gy does not seem to compromise OS93 but is likely 
to cause neurocognitive adverse events if, in the future, 
elderly patients with glioblastoma live longer because 
of improved systemic treatment. Neither accelerated 
hyperfractionated or hypofractionated regimens nor 
brachytherapy, radiosurgery or a stereo tactic radio-
therapy boost are superior to standard radio therapy 
regimens in terms of OS57. Concomitant radiotherapy 
and chemotherapy with temozolomide (75 mg/m2 daily 
throughout radiotherapy, including at weekends) plus six 
cycles of maintenance temozolomide (150–200 mg/m2, 
5 out of 28 days) is the standard of care for adults with 
newly diagnosed glioblastoma who are in good general 
and neurological condition and are aged <70 years59. 
The addition of temozolomide to hypofractionated 
radiotherapy54 has also been shown to improve OS in 
patients aged ≥60 years94. The benefit from temozolo-
mide is largely limited to patients with MGMT promoter- 
methylated glioblastoma94,95. The results of the NOA-08 
(refs96,97) and Nordic trials98 led to MGMT promoter 
methylation testing becoming standard practice in 
many European countries for the management of elderly 
patients not considered eligible for combined modality 
treatment: patients with tumours lacking MGMT pro-
moter methylation or of unknown MGMT promoter 
methylation status should be treated with hypofraction-
ated radiotherapy alone whereas those with tumours 
with MGMT promoter methylation status should 
receive temozolomide alone (5 out of 28 days until dis-
ease progression or for 12 months)97. Until 2016, the 
broad consensus was that the results of all trials involv-
ing patients with tumours without MGMT promoter 
methylation showed no detriment from the omission 
of temozolomide99, challenging the view that this agent 
IDH-mutant glioma
Treatment at diagnosis
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Fig. 2 | Clinical pathway for iDH- mutant gliomas. KPS, Karnofsky performance status; PCV, procarbazine, lomustine  
and vincristine.
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should be used in every patient regardless of MGMT 
promoter methylation status. This notion has become 
controversial again after a minor OS prolongation with 
radiotherapy plus temozolomide versus radiotherapy 
alone was observed in elderly patients with glioblasto-
mas lacking MGMT promoter methylation94 and with 
the negative outcome of the CheckMate 498 trial100.
An open- label phase III trial of the addition of 
tumour- treating fields to maintenance temozolomide 
in patients with newly diagnosed glioblastoma revealed 
superior PFS and OS outcomes across all patient and 
tumour subgroups101, without relevant differences in 
QOL between arms102. However, questions have been 
raised regarding the mode of action, the study design 
without a sham control, the interpretation of data 
and the effect on health- related QOL in the general 
patient population103. Additionally, the feasibility and 
cost- effectiveness of tumour- treating fields as a stan-
dard of care for newly diagnosed glioblastoma remain 
highly controversial104. A focus on supportive and 
palliative care is appropriate for patients with large or 
multifocal lesions with a low KPS, notably if they are 
unable to provide consent for further therapy after 
biopsy74.
No benefit has been reported from increasing the 
dose of temozolomide in patients with newly diagnosed 
disease105 nor from extending the duration of chemother-
apy beyond six cycles106. However, combining temozolo-
mide with lomustine in the newly diagnosed setting might 
extend OS in patients with MGMT promoter- methylated 
glioblastoma107. This phase III trial involved a small 
cohort, did not show superior PFS for the combination 
and might deprive patients from lomustine, the standard 
of care at recurrence; thus, the use of this regimen appears 
to be largely restricted to some sites in German- speaking 
countries. The results of two phase III trials involving 
adults with glioblastoma demonstrated a prolongation 
of PFS (3–4 months) but not of OS when bevacizumab 
was added to temozolomide chemoradiotherapy108,109. 
A phase II trial involving a small cohort of elderly 
patients with MGMT promoter- unmethylated glio-
blastoma had similar results110; however, the clinical 
significance of such PFS gains is unclear because the 
reliability of assessing progression by neuroimaging can 
be questioned and because data from the RTOG 0825 
trial raised concerns of early cognitive decline in patients 
treated with bevacizumab109. Bevacizumab has therefore 
not been approved for the treatment of newly diagnosed 
glioblastoma, with very few exceptions worldwide, but 
could be useful in patients with large tumours who are 
highly symptomatic and who might not otherwise tole r-
ate radiotherapy. In the field of immunotherapy, negative 
phase III trials for OS include that of the EGFR- targeted 
vaccine rindopepimut in patients with EGFRvIII- positive 
glioblastoma111 and that of the immune checkpoint 
inhibitor nivolumab in patients with MGMT promoter 
unmethylated glioblastoma100.
Standard- of- care treatments for patients with recur-
rent glioblastoma are not well defined; treatment is 
selected on the basis of prior therapy, age, KPS, MGMT 
promoter methylation status and patterns of disease 
progression (fig. 3). Second surgery is an option for 
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Fig. 3 | Clinical pathway for iDH- wild- type glioblastomas, WHO grade 4. KPS, Karnofsky performance status.
Nature reviews | CliniCal OnCOlOgy
e v i d e n c e - B a s e d  g u i d e l i n e s
~20–30% of patients, commonly with symptomatic 
but circumscribed relapses diagnosed not earlier than 
6 months after initial surgery. Second surgery earlier 
than 6 months after initial surgery increases the risk of 
unnecessary intervention on the basis of pseudopro-
gression and is unlikely to provide durable benefit if the 
initial surgery followed by radiotherapy did not provide 
tumour control for more than a few months. Second 
surgery can also be considered upon early progression 
in symptomatic patients who might not have had ade-
quate initial surgery. This procedure might improve 
post- recurrence survival in patients who are candidates 
for gross total resection of enhancing tumour112.
The efficacy of re- irradiation and the value of 
amino acid PET for target delineation remain debated. 
Radiation fractionation depends on tumour size. Larger 
lesions require smaller single fraction sizes to improve 
the safety and tolerability. Doses of conventional or 
near conventional fractionation have been tested as 
well as higher doses per fraction (5–6 Gy) using stereo-
tactic hypofractionated radiotherapy to a total dose 
of 30–36 Gy or even radiosurgery with a single dose of 
15–20 Gy, all with acceptable toxicity profiles113. The 
only RCT exploring bevacizumab plus radiotherapy 
versus bevacizumab alone reported improved PFS but 
not OS114.
The main systemic treatment options for patients 
with disease progression include nitrosoureas, temozo-
lomide rechallenge, bevacizumab (depending on avail-
ability) or inclusion into a clinical trial. Lomustine 
(90–110 mg/m2) has never been shown to have superi-
ority over another agent in an RCT60 but is increasingly 
considered as the most appropriate standard of care 
on the basis of its activity as the control arm of several 
RCTs65,115 and is also used in the AGILE trial116, with 
6- month PFS rates of ~20%60. Similar results have been 
reported with alternative dosing schedules of temozolo-
mide but activity is probably limited to patients with 
tumours with MGMT promoter methylation117,118. No 
data from RCTs support the view that dose- intensified 
schedules are superior to standard- dose temozolo-
mide in patients with recurrent glioblastoma after a 
temozolomide- free interval.
Bevacizumab is not approved for patients with recur-
rent glioblastoma in the European Union, although it 
has been approved for this indication in other countries 
on the basis of objective response rates of ~30% in two 
uncontrolled phase II trials66,67. Bevacizumab has not 
been compared with placebo, and an effect on OS was 
not observed upon combination with lomustine as com-
pared with lomustine alone65. To date, no active combi-
nation partner for bevacizumab to prolong OS has been 
identified. The main value of this agent in routine clini-
cal practice is transient symptom control and the option 
for sparing treatment with steroids in symptomatic 
patients with large tumours.
In other studies of potential treatments for recurrent 
glioblastoma, nivolumab was not superior to bevaciz-
umab119 and tumour- treating fields were not superior 
to physician’s choice of best treatment120. So far, only 
a limited role for targeted therapy in recurrent glio-
blastoma has been shown12. Approximately 50% of the 
rare epithelioid glioblastomas, an entity that remains 
controversial because of its similarity to anaplastic 
pleomorphic xanthoastrocytoma, harbour BRAFV600E 
mutations. Patients with such tumours might benefit 
from BRAF inhibitors, at least in the setting of disease 
recurrence121.
Recommendations. 
•	The standard of care for patients with IDH- wild- type 
glioblastoma aged <70 years and with a KPS >70 
includes resection as feasible or biopsy followed by 
involved- field radiotherapy and concomitant radio-
therapy and six cycles of maintenance temozolo-
mide chemotherapy (EORTC 26981- NCIC CE.3)59. 
C: I; L: A.
•	Temozolomide might only be active in patients with 
MGMT promoter- methylated tumours whereas 
its activity in patients with MGMT promoter- 
unmethylated tumours is probably marginal95. 
C: II; L: B.
•	 Elderly patients not considered candidates for 
temozolomide chemoradiotherapy should be treated 
on the basis of MGMT promoter methylation status 
(NOA-08, Nordic Trial) with radiotherapy (such as 
15 × 2.66 Gy) or temozolomide (5 out of 28 days) 
alone96,98,97. C: II; L: B.
•	At recurrence, standards of care are less well defined. 
Surgery and radiotherapy might be considered. 
Nitrosourea regimens, temozolomide rechallenge 
and, with consideration of the country- specific label, 
bevacizumab are options of pharmacotherapy but an 
impact on OS remains unproven. When available, 
recruitment into appropriate clinical trials should be 
considered. C: II; L: B.
H3 K27M- mutant diffuse midline glioma, WHO grade 4. 
This tumour type includes the majority of brainstem, 
thalamic and spinal diffuse gliomas in children and 
adults. Surgical options are limited and benefits from 
treatment options beyond radiotherapy have not been 
established because these tumours are rare and have 
not been studied in dedicated trials. In these tumours, 
the MGMT promoter is usually unmethylated. The 
prognosis of patients with this tumour type is poor.
H3.3 G34- mutant diffuse hemispheric glioma, WHO 
grade 4. These tumours mostly occur in adolescents and 
young adults and the MGMT promoter is more often 
methyl ated than unmethylated122. These tumours were 
pre viously classified as IDH- wild- type glioblastomas 
and, thus, a reasonable treatment approach for such 
patients is chemoradiotherapy.
Discouraged treatments. Steroids should not be given to 
treat asymptomatic or minimally symptomatic oedema 
and should be tapered as soon as possible, considering 
their unfavourable safety profile upon long- term admin-
istration. Furthermore, steroid use has been shown to be 
a negative prognostic factor for OS in patients with glio-
blastoma from three separate large cohorts123 and might 
interfere with the efficacy of radiotherapy, chemotherapy 
and immunotherapy.
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Furthermore, we advocate against the use of any 
treatment beyond confirmed progression on that 
same treatment, including bevacizumab124 and tumour- 
treating fields, because the clinical benefit of this prac-
tice has not been established. Several chemotherapy 
regimens commonly used to treat other tumour types, 
including irinotecan and platinum compounds, are 
known not to be active against gliomas and should 
therefore not be used in this setting.
Given the poor outcomes of many patients with 
diffuse gliomas, new treatment concepts emerge and 
vanish that have never been tested in appropriate RCTs 
and the use of which outside a clinical trial is discour-
aged. Examples include the cocktail of repurposed 
drugs referred to as CUSP9, cannabinoids, methadone, 
sulfasalazine and valproate (except for seizure control).
Conclusions
The revision of the WHO Classification of Tumors of 
the Central Nervous System1 has led to major changes 
in the way we routinely diagnose and treat patients with 
gliomas. The diagnosis and management plans should 
follow multidisciplinary tumour board recommenda-
tions throughout the course of disease. Multidisciplinary 
tumour board meetings are the fora for the discussion 
of whether treatments should be delivered locally or 
at a specialized centre and in inpatient or outpatient 
settings as well as to determine which neurorehabil-
itation measures would be useful. Local and national 
guidelines as well as EANO guidelines provide further 
guidance. Guidelines reflect knowledge and consensus 
at a given time; information on future updates will be 
posted on the EANO website. For many of the newly 
defined disease entities in the latest WHO classifica-
tion, data on specific treatments and outcomes are not 
yet available; extrapolating data from clinical trials to 
these novel entities remains challenging. Well- designed, 
molecularly enriched RCTs are necessary to substantiate 
some of the treatment recommendations of the present 
guidelines.
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